Xiaosong Gu1,2, Jiang Xu1, Xiao-Ping Yang1, Edward Peterson3, Pamela Harding1. 1. Hypertension and Vascular Research Division, Department of Internal Medicine, Henry Ford Hospital, Detroit, MI, 48202, USA. 2. Department of Cardiology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215004, China. 3. Department of Public Health Sciences, Henry Ford Hospital, Detroit, MI, 48202, USA.
Abstract
NEW FINDINGS: What is the central question of this study? What is the cardioprotective role of fractalkine neutralization in heart failure and what are the mechanisms responsible? What is the main finding and its importance? The concentration of fractalkine is increased in the left ventricle of mice with myocardial infarction, similar to the increases in plasma from heart failure patients. The present study shows a clear beneficial effect of neutralizing fractalkine in a model of myocardial infarction, which results in increased survival. Such an approach may be worthwhile in human patients. Concentrations of the chemokine fractalkine (FKN) are increased in patients with chronic heart failure, and our previous studies show that aged mice lacking the prostaglandin E2 EP4 receptor subtype (EP4-KO) have increased cardiac FKN, with a phenotype of dilated cardiomyopathy. However, how FKN participates in the pathogenesis of heart failure has rarely been studied. We hypothesized that FKN contributes to the pathogenesis of heart failure and that anti-FKN treatment prevents heart failure induced by myocardial infarction (MI) more effectively in EP4-KO mice. Male EP4-KO mice and wild-type littermates underwent sham or MI surgery and were treated with an anti-FKN antibody or control IgG. At 2 weeks post-MI, echocardiography was performed and hearts were excised for determination of infarct size, immunohistochemistry and Western blot of signalling molecules. Given that FKN protein levels in the left ventricle were increased to a similar extent in both strains after MI and that anti-FKN treatment improved survival and cardiac function in both strains, we subsequently used only wild-type mice to examine the mechanisms whereby anti-FKN is cardioprotective. Myocyte cross-sectional area and interstitial collagen fraction were reduced after anti-FKN treatment, as were macrophage migration and gelatinase activity. Activation of ERK1/2 and p38 MAPK were reduced after neutralization of FKN. In vitro, FKN increased fibroblast proliferation. In conclusion, increased FKN contributes to heart failure after MI. This effect is not exacerbated in EP4-KO mice, suggesting that there is no link between FKN and lack of EP4. Overall, inhibition of FKN may be important to preserve cardiac function post-MI.
NEW FINDINGS: What is the central question of this study? What is the cardioprotective role of fractalkine neutralization in heart failure and what are the mechanisms responsible? What is the main finding and its importance? The concentration of fractalkine is increased in the left ventricle of mice with myocardial infarction, similar to the increases in plasma from heart failure patients. The present study shows a clear beneficial effect of neutralizing fractalkine in a model of myocardial infarction, which results in increased survival. Such an approach may be worthwhile in human patients. Concentrations of the chemokine fractalkine (FKN) are increased in patients with chronic heart failure, and our previous studies show that aged mice lacking the prostaglandin E2 EP4 receptor subtype (EP4-KO) have increased cardiac FKN, with a phenotype of dilated cardiomyopathy. However, how FKN participates in the pathogenesis of heart failure has rarely been studied. We hypothesized that FKN contributes to the pathogenesis of heart failure and that anti-FKN treatment prevents heart failure induced by myocardial infarction (MI) more effectively in EP4-KO mice. Male EP4-KO mice and wild-type littermates underwent sham or MI surgery and were treated with an anti-FKN antibody or control IgG. At 2 weeks post-MI, echocardiography was performed and hearts were excised for determination of infarct size, immunohistochemistry and Western blot of signalling molecules. Given that FKN protein levels in the left ventricle were increased to a similar extent in both strains after MI and that anti-FKN treatment improved survival and cardiac function in both strains, we subsequently used only wild-type mice to examine the mechanisms whereby anti-FKN is cardioprotective. Myocyte cross-sectional area and interstitial collagen fraction were reduced after anti-FKN treatment, as were macrophage migration and gelatinase activity. Activation of ERK1/2 and p38 MAPK were reduced after neutralization of FKN. In vitro, FKN increased fibroblast proliferation. In conclusion, increased FKN contributes to heart failure after MI. This effect is not exacerbated in EP4-KO mice, suggesting that there is no link between FKN and lack of EP4. Overall, inhibition of FKN may be important to preserve cardiac function post-MI.
Authors: Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; David Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Graham Nichol; Nina P Paynter; Pamela J Schreiner; Paul D Sorlie; Joel Stein; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner Journal: Circulation Date: 2013-01-01 Impact factor: 29.690
Authors: Y Pan; C Lloyd; H Zhou; S Dolich; J Deeds; J A Gonzalo; J Vath; M Gosselin; J Ma; B Dussault; E Woolf; G Alperin; J Culpepper; J C Gutierrez-Ramos; D Gearing Journal: Nature Date: 1997-06-05 Impact factor: 49.962
Authors: K F Fox; M R Cowie; D A Wood; A J Coats; J S Gibbs; S R Underwood; R M Turner; P A Poole-Wilson; S W Davies; G C Sutton Journal: Eur Heart J Date: 2001-02 Impact factor: 29.983
Authors: L A Robinson; C Nataraj; D W Thomas; D N Howell; R Griffiths; V Bautch; D D Patel; L Feng; T M Coffman Journal: J Immunol Date: 2000-12-01 Impact factor: 5.422
Authors: Cathrine Husberg; Ståle Nygård; Alexandra Vanessa Finsen; Jan Kristian Damås; Arnoldo Frigessi; Erik Oie; Anne Waehre; Lars Gullestad; Pål Aukrust; Arne Yndestad; Geir Christensen Journal: J Mol Cell Cardiol Date: 2008-05-28 Impact factor: 5.000
Authors: Ivanita Stefanon; María Valero-Muñoz; Aurélia Araújo Fernandes; Rogério Faustino Ribeiro; Cristina Rodríguez; Maria Miana; José Martínez-González; Jessica S Spalenza; Vicente Lahera; Paula F Vassallo; Victoria Cachofeiro Journal: PLoS One Date: 2013-05-31 Impact factor: 3.240
Authors: Timothy D Bryson; Jacob Ross; Edward Peterson; Pamela Harding Journal: Prostaglandins Other Lipid Mediat Date: 2019-06-20 Impact factor: 3.072
Authors: Irene Müller; Kathleen Pappritz; Konstantinos Savvatis; Kerstin Puhl; Fengquan Dong; Muhammad El-Shafeey; Nazha Hamdani; Isabell Hamann; Michel Noutsias; Carmen Infante-Duarte; Wolfgang A Linke; Sophie Van Linthout; Carsten Tschöpe Journal: PLoS One Date: 2017-08-11 Impact factor: 3.240
Authors: Andreas Mangold; Thomas M Hofbauer; Anna S Ondracek; Tyler Artner; Thomas Scherz; Walter S Speidl; Konstantin A Krychtiuk; Roela Sadushi-Kolici; Johannes Jakowitsch; Irene M Lang Journal: Sci Rep Date: 2019-11-08 Impact factor: 4.379
Authors: Christina Katharina Weisheit; Jan Lukas Kleiner; Maria Belen Rodrigo; Sven Thomas Niepmann; Sebastian Zimmer; Georg Daniel Duerr; Mark Coburn; Christian Kurts; Stilla Frede; Lars Eichhorn Journal: PLoS One Date: 2021-01-07 Impact factor: 3.240